Number of the records: 1
Chemoimmunotherapy in mice carrying HPV16-associated, MHC class I+ and class I- tumours: effects of CBM-4A potentiated with IL-2, IL-12, GM-CSF and genetically modified tumour vaccines
- 1.0191582 - UMG-J 20033049 RIV GR eng J - Journal Article
Indrová, Marie - Bubeník, Jan - Mikyšková, Romana - Mendoza, Luis - Šímová, Jana - Bieblová, Jana - Jandlová, Táňa - Jinoch, P. - Šmahel, M. - Vonka, V. - Pajtasz-Piasecka, E.
Chemoimmunotherapy in mice carrying HPV16-associated, MHC class I+ and class I- tumours: effects of CBM-4A potentiated with IL-2, IL-12, GM-CSF and genetically modified tumour vaccines.
International Journal of Oncology. Roč. 22, č. 3 (2003), s. 691-695. ISSN 1019-6439. E-ISSN 1791-2423
R&D Projects: GA MZd NC7148; GA ČR GA301/00/0114; GA ČR GA301/01/0985; GA AV ČR IAA5052203; GA AV ČR IAA7052002
Grant - others:KBN(PL) P04A12314; Liga proti rakovině(CZ) -
Institutional research plan: CEZ:AV0Z5052915
Keywords : chemotherapy-induced residual tumour disease * immunotherapy * HPV16-associated tumours
Subject RIV: FD - Oncology ; Hematology
Impact factor: 2.536, year: 2003
The effectiveness of chemoimmunotherapy with ifosfamide derivative CBM-4A and recombinant IL-2, IL-12, GM-CSF, or genetically modified, cytokine-producing tumour vaccines was examined in mice carrying HPV16-associated, MHC class I+ and class I- tumours. In mice carrying the MHC class I- tumour the effects of adjuvant cytokine therapy were substantially weaker than in mice carrying MHC class I+ tumour inoculum.
Permanent Link: http://hdl.handle.net/11104/0087324
Number of the records: 1